Cardiotrophin-1 as a marker of function and myocardial condition in essential hypertension and chronic heart failure


Keywords: essential hypertension, chronic heart failure, left ventricular hypertrophy, Cardiotrophin-1.

Abstract

Purpose of the work is to analyze the diagnostic and predictive value of Cardiotrophin-1 in patients with essential hypertension and chronic heart failure. The analysis is based on a review of articles and research for 2013-2018, using the PubMed databases, eLIBRARY.RU, Web of Science. In its prevalence, essential hypertension is one of the leaders among cardiovascular diseases. In Ukraine, as in the rest of the world, progressive growth in the number of essential hypertension complications is observed annually. One of the most common complications is chronic heart failure. The frequency of hospitalization and fatal cases of chronic heart failure worldwide remains high, so the search for specific markers that will help to assess the cardiovascular risk of patients with chronic heart failure and the effectiveness of treatment is becoming increasingly relevant. This article presents data that may indicate the use of Cardiotrophin-1 as a marker for early diagnosis of essential hypertension and its complications. Cardiotrophin-1 is a protein with a molecular weight of 21.5 kDa, a representative of the interleukin 6 superfamily, capable of inducing hypertrophy and hyperplasia of cardiomyocytes both in vitro and in vivo.

Author Biographies

M.O. Matokhniuk

Matokhniuk Maryna, postgraduate student department of Internal medicine of medical faculty №2 National Pirogov Memorial Medical University; ORCID https://orcid.org/0000-0001-5968-0512

О.V. Limanskiy

Limanskiy Oleksandr assistant department of Internal medicine of medical faculty №2 National Pirogov Memorial Medical University, ORCID https://orcid.org/0000-0002-5725-1340

V. M. Zhebel

Zhebel Vadym, Chief of the chair of internal medicine of medical faculty № 2, National Pirogov Memorial Medical University, Vinnytsya, MD.

O.L. Starzhynska

Starzhynska Olha, PhD assistant professor of Department of Internal Medicine of the of Medical Faculty №2, Vinnitsa Pirogov Memorial Medical Institute, ORCID https://orcid.org/0000-0003-3804-3818.

References

1. Berezin, A. E. (2012). Kardiotrofin-1 — novyj prognosticheskij marker serdechnoj nedostatochnosti (obzor literatury) [Cardiotrophin-1 — a new prognostic marker of heart failure (literature review)]. Ukr. med. chasopys – Ukr. med. a magazine, 1 (87), 75–80.

2. Kolesnyk, M. Yu. (2015). Dynamika biomarkeriv kardialnoho remodeliuvannia kardiotrofina-1 ta aneksynu v v cholovikiv z arterialnoiu hipertenziieiu pid vplyvom kombinovanoi terapii [Dynamics of cardiomedial remodeling of cardiotrophin-1 and annexin v in men with arterial hypertension under the influence of combination therapy]. Aktualni problemy suchasnoi medytsyny: Visnyk ukrainskoi medychnoi stomatolohichnoi akademii – Actual problems of modern medicine: Bulletin of the Ukrainian Medical Stomatological Academy, 1 (49), 110–115.

3. Kolesnik, M. Yu. (2014). Kardiotrofin-1 — novyj marker remodelirovaniya miokarda pri arterialnoj gipertenzii s narusheniyami metabolizma glyukozy (kliniko-eksperimentalnoe issledovanie) [Cardiotrophin-1 - a new marker of myocardial remodeling in arterial hypertension with impaired glucose metabolism (clinical and experimental study)]. Odeskyi medychnyi zhurnal – Odessa Medical Journal, 6 (146), 65–71.

4. Pashkova Yu. P. (2016). Strukturno-funktsIonalni pokazniki miokarda u cholovikiv meshkantsiv Podilskogo regionu Ukrayini z gipertoniichnoyu hvoroboyu II stadiyi, nosiyiv riznih variantiv gena mozkovogo natriyuretichnogo peptidu. [Structural and functional parameters of myocardium in men of the Podillya region of Ukraine with hypertension II stage, carriers of various variants of the brain of the natriuretic peptide brain peptide] Visnik vinnitskogo natsionalnogo medichnogo universitetu- Herald of the Vinnytsia National Medical University, 1, 2, ( 20), 165–171.

5. Starzhynska O. L. (2013). Polimorfizm heniv renin-anhiotenzyn-aldosteronovoi systemy v kardiolohii. Biomedical and biosocial anthropology. [Polymorphism of the renin-angiotensin-aldosterone system genes in cardiology] Biomedical and biosocial anthropology – Biomedical and biosocial anthropology, 20, 204–207.

6. Tokmachev, R. E. (2015). Uchastie citokinov v razvitii serdechnoj nedostatochnosti [Cytokine involvement in the development of heart failure]. Molodoj uchenyj – Young scientist, 3, 296–298.

1. Aguilar-Melero, P., Luque, A. & Machuca, M. M. (2013). Cardiotrophin-1 reduces ischemia/reperfusion injury during liver transplant. P. J. Surg. Res., 181 (2), 83–91. doi: 10.1016/j.jss.2012.07.046.

2. Burger, R., Günther, A., Klausz, K., Staudinger, M., Peipp, M., Maria, E., … Gramatzki, M. (2017). “Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth”. Haematologica, 102 (2), 381–390. doi: 10.3324/haematol.2016.145060.

3. Celik, A., Sahin, S., Koc, F., Karayakali, M., Sahin, M., Benli, I. … Ceyhan, K. (2012). Cardiotrophin-1 plasma levels are increased in patients with diastolic heart failure. Medical science monitor: international medical journal of experimental and clinical research, 18 (1), 25–31. doi: 10.12659/MSM.882197.

4. Cienfuegos, A., J., Rotellar, F., Baixauli, J., Martínez-Regueira, F., Pardo, F. & Hernández-Lizoáin, J. L. (2014). Liver regeneration – the best kept secret. A model of tissue injury response. Rev. esp. enferm. dig., 106 (3), 171–194.

5. Dongmei, Wang & Xiaoying, Li. (2013). Cardiotrophin-1 (CTF1) ameliorates glucose-uptake defects and improves memory and learning deficits in a transgenic mouse model of Alzheimer's disease. Pharmacology, Biochemistry and Behavior, 107, 48–57. doi: 10.1016/j.pbb.2013.03.003.

6. Gamella-Pozuelo, L., Fuentes-Calvo, I. & Gómez-Marcos, M. A. (2015). Plasma Cardiotrophin-1 as a Marker of Hypertension and Diabetes-Induced Target Organ Damage and Cardiovascular Risk. Medicine, 94 (30), e1218. doi: 10.1097/MD.0000000000001218.

7. García-Cenador, M. B. & Lopez-Novoa, J. M. (2013). Effects and mechanism of organ protection by cardiotrophin-1. Review. Curr. Med. Chem., 20 (2), 246–256. doi: 10.2174/0929867311320020005.

8. Hanae, Konii & Kengo, Sato. (2013). Stimulatory Effects of Cardiotrophin 1 on Atherosclerosis. Hypertension, 62, 942–950. doi:10.1161/HYPERTENSIONAHA.113.01653.

9. Hung, H. C., Lu, F. H., Wu, H. T., Ou, H. Y. & Yang, Y. C. (2015). Cardiotrophin-1 is inversely associated with obesity in non-diabetic individuals. Scientific reports, 5, 17438. doi:10.1038/srep17438.

10. Kannel, W. B. & Cobb, J. (1992). Left ventricular hypertrophy and mortality – results from the Framingham Study. Cardiology, 81 (4–5), 291–8. DOI: 10.1159/000175819.

11. López-Yoldi, M. & Moreno-Aliaga, M. J. (2015). Cardiotrophin-1: A multifaceted cytokine. Cytokine and Growth Factor Rev., 26 (5), 523–532. doi: 10.1016/j.cytogfr.2015.07.009.

12. Monserrat, L., López, B., González, A., Hermida, M., Fernández, X., Ortiz, M., Barriales-Villa, R., Castro-Beiras, A., … Díez, J. (2010). Cardiotrophin-1 plasma levels are associated with the severity of hypertrophy in hypertrophic cardiomyopathy. European heart journal, 32(2), 177–83. doi: 10.1093/eurheartj/ehq400.

13. Natal, C., Fortuno, M. A., & Restituto, P. (2008). Cardiotrophin-1 is expressed in adipose tissue and upregulated in the metabolic syndrome. Am. J. Physiol. Endocrinol. Metab., 294 (1), 52-60.

14. Pennica, D., Swanson, T. A., Shaw, K. J., Shaw, K. J., Kuang, W. J., Gray, C. L. Wood, W. I. (1996). Human cardiotrophin: protein and genetic structure, biological and binding activities, and chromosomal localization. Cytokine, 8, 183–189. DOI: 10.1006/cyto.1996.0026.

15. Ribeiro-Samora, G. A. (2017). Inflammation and oxidative stress in heart failure: effects of exercise intensity and duration. Brazilian Journal of Medical and Biological Research, 50 (9), e6393. doi: 10.1590/1414-431X20176393.

16. Schwerd, T., Twigg, S.R.F., Aschenbrenner, D., Manrique, S., Miller, K. A., Taylor, I. B. … Uhlig, H. H. (2017). A biallelic mutation in IL6ST encoding the GP130 coreceptor causes immunodeficiency and craniosynostosis. J. Exp. Med. 214 (9), 2547–2562. doi: 10.1084/jem.20161810.

17. Segers, V., Brutsaert, D. L. & De Keulenaer, G. W. (2018). Cardiac Remodeling: Endothelial Cells Have More to Say Than Just NO. Frontiers in physiology, 9, 382. doi:10.3389/fphys.2018.00382.

18. Song, K., Wang, S., Huang, B., Luciano, A., Srivastava, R. & Mani, A. (2014). Plasma cardiotrophin-1 levels are associated with hypertensive heart disease: a meta-analysis. Journal of clinical hypertension (Greenwich, Conn.), 16 (9), 686–92. doi: 10.1111/jch.12376.

19. Takahashi, N., Saito, Y., Kuwahara, K., Harada, M., Tanimoto, K., Nakagawa, Y., ... Nakao, K. (2005). Hypertrophic responses to cardiotrophin-1 are not mediated by STAT3, but via a MEK5-ERK5 pathway in cultured cardiomyocytes. Journal of Molecular and Cellular Cardiology, 38 (1), 185-192. https://doi.org/10.1016/j.yjmcc.2004.10.016.

20. Takayoshi Tsutamoto, Atsuyuki Wada, & Keiko Maeda, (2001). Relationship between plasma level of cardiotrophin-1 and left ventricular mass index in patients with dilated cardiomyopathy. Journal of the American College of Cardiology, 38 (5). https://doi.org/10.1016/S0735-1097(01)01576-5.

21. Takuya Watanabe, Hanae Konii & Kengo Sato (2018). Emerging Roles of Cardiotrophin-1 in the Pathogenesis and Biomarker of Atherosclerosis. MDPI, 1, 94–105. doi: 10.3390/j1010010.

22. Talwar, S., & Downie, P. F. (2001) Plasma N-terminal pro BNP and cardiotrophin-1 are elevated in aortic stenosis. Eur. J. Heart Fail, 3, 15–19.

7. Tokito, A., Jougasaki, M., Ichiki, T. & Hamasaki, S. (2013). Cardiotrophin-1 induces matrix metalloproteinase-1 in human aortic endothelial cells. PloS One, 8 (7), e68801. doi:10.1371/journal.pone.0068801.
Published
2019-03-01
How to Cite
Matokhniuk, M., LimanskiyО., Zhebel, V. M., & Starzhynska, O. (2019). Cardiotrophin-1 as a marker of function and myocardial condition in essential hypertension and chronic heart failure. Reports of Vinnytsia National Medical University, 23(1), 172-177. https://doi.org/https://doi.org/10.31393/reports-vnmedical-2019-23(1)-31